Lonza and Fosun Chinese biopharm generic JV will "protect customer IP"
This article was originally published in Scrip
Executive Summary
With Chinese pharma companies keen to seek further growth for their generic portfolios amid upcoming major patent expiries, and also facing pressure to improve the quality of their products, one solution is to team up with a reputable international contract manufacturer.